MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company advancing molecularly targeted intraoperative imaging, today announced the initiation of VISUALIZE 2, a Phase 3 ...
The Phase 3 VISUALIZE 2 study is designed to confirm the safety and efficacy of abenacianine for use in lung cancer surgery. This randomized, open-label, multi-center trial will enroll 132 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results